IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Michael Cuenod

APPLICATION NO: 10/586071

FILED: January 14, 2005

FOR: Diagnostic and Treatment of a Mental Disorder

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of April 6, 2010, a response to which is due by July 6, 2010 with a two-month extension of time, Applicants elect the claims of Group I, claims 1-11 and 40-42, drawn to diagnostic methods determining the level of expression of a gene. This election is without traverse.

In response to the requirement for a species election among the different genes involved in regulating the intracellular GSH level, Applicants elect the gene glutamate-cysteine ligase (GCL). The claims readable on the elected species are claims 1-3, 5-11 and 40-42. This species election is without traverse.

Applicants request a two-month extension of time to respond. Please charge the \$490,00 fee to Deposit Account No. 50-4409. If necessary, the Commissioner is hereby authorized to charge payment or credit any overpayment to Deposit Account No. 50-4409 for any additional fees under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Should the Examiner have any questions, please contact the undersigned attorney. An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. 220 Massachusetts Ave Cambridge, MA 02139 (617) 871-3346

Date: June 25, 2010

John T. Prince Attorney for Applicant

Reg. No. 43,019